? The goal of this proposal is to continue and expand the existing """"""""COBRE Center for Cancer Experimental Therapeutics."""""""" Four state institutions the University of Kansas-Lawrence (KU), the KU Medical Center (KUMC), Kansas State University (KSU), and Wichita State University (WSU), combine resources and faculty to establish a Center to mentor junior faculty in cancer-related research and to create novel infrastructure needed for experimentation at the interface between chemistry and biology. Funds are requested for the support of five projects. Project investigators are partnered with established, active, senior faculty who will serve as their mentors. In addition, the competitive First Award Program to enhance the competitiveness of future recruits, and a program for start-up enhancement packages will be established. Support from the University of Kansas and the Kansas Technology Enterprise Corporation (KTEC) together with NIH-COBRE funding will provide continued backing for two existing Core facilities and a new Core. Two COBRE Cores, Medicinal Chemistry and High Throughput Screening, started in the last granting period, will receive continued support. A new Core facility for the generation of transgenic and knock-out animals will be established. These Cores are needed to identify novel biological targets, and novel bioactive compounds, that will be useful basic biomedical research tools, and potential therapeutic agents. The Core facilities will be operated by an experienced group of investigators with expertise in the areas of medicinal and combinatorial chemistry, cell and molecular biology, biochemistry, cancer cell biology, pharmacology and the development of novel bioassays for compound and cellular target identification. The combination of expertise for the identification of novel drug targets, generation and analysis of novel compounds, together with that for the development of bioassays for screening, offers a unique opportunity for multidisciplinary research. At the end of the granting period, the Center will be the KU-Lawrence part of a new joint Cancer Center with KU-Lawrence and the KU Medical Center. The three COBRE Core laboratories will become University-supported research service laboratories. ? ?

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
Exploratory Grants (P20)
Project #
2P20RR015563-06
Application #
6988669
Study Section
Special Emphasis Panel (ZRR1-RI-8 (01))
Program Officer
Sayre, Michael
Project Start
2000-09-30
Project End
2010-04-30
Budget Start
2005-09-22
Budget End
2006-04-30
Support Year
6
Fiscal Year
2005
Total Cost
$1,786,254
Indirect Cost
Name
University of Kansas Lawrence
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
076248616
City
Lawrence
State
KS
Country
United States
Zip Code
66045
Subramanian, Chitra; Grogan, Patrick T; Opipari, Valerie P et al. (2018) Novel natural withanolides induce apoptosis and inhibit migration of neuroblastoma cells through down regulation of N-myc and suppression of Akt/mTOR/NF-?B activation. Oncotarget 9:14509-14523
Ishiguro, Susumu; Kawabata, Atsushi; Zulbaran-Rojas, Alejandro et al. (2018) Co-treatment with a C1B5 peptide of protein kinase C? and a low dose of gemcitabine strongly attenuated pancreatic cancer growth in mice through T cell activation. Biochem Biophys Res Commun 495:962-968
He, Chenchen; Duan, Shaofeng; Dong, Liang et al. (2017) Characterization of a novel p110?-specific inhibitor BL140 that overcomes MDV3100-resistance in castration-resistant prostate cancer cells. Prostate 77:1187-1198
White, Peter T; Subramanian, Chitra; Zhu, Qing et al. (2016) Novel HSP90 inhibitors effectively target functions of thyroid cancer stem cell preventing migration and invasion. Surgery 159:142-51
Ohta, Naomi; Ishiguro, Susumu; Kawabata, Atsushi et al. (2015) Human umbilical cord matrix mesenchymal stem cells suppress the growth of breast cancer by expression of tumor suppressor genes. PLoS One 10:e0123756
Li, Benyi; Thrasher, James Brantley; Terranova, Paul (2015) Glycogen synthase kinase-3: a potential preventive target for prostate cancer management. Urol Oncol 33:456-63
Ishiguro, Susumu; Yoshimura, Kiyoshi; Tsunedomi, Ryouichi et al. (2015) Involvement of angiotensin II type 2 receptor (AT2R) signaling in human pancreatic ductal adenocarcinoma (PDAC): a novel AT2R agonist effectively attenuates growth of PDAC grafts in mice. Cancer Biol Ther 16:307-16
Grogan, Patrick T; Sarkaria, Jann N; Timmermann, Barbara N et al. (2014) Oxidative cytotoxic agent withaferin A resensitizes temozolomide-resistant glioblastomas via MGMT depletion and induces apoptosis through Akt/mTOR pathway inhibitory modulation. Invest New Drugs 32:604-17
Li, Benyi; Sun, Aijing; Jiang, Wencong et al. (2014) PI-3 kinase p110?: a therapeutic target in advanced prostate cancers. Am J Clin Exp Urol 2:188-98
Bibis, Stergios S; Dahlstrom, Kelly; Zhu, Tongtong et al. (2014) Characterization of Leishmania major phosphatidylethanolamine methyltransferases LmjPEM1 and LmjPEM2 and their inhibition by choline analogs. Mol Biochem Parasitol 196:90-9

Showing the most recent 10 out of 240 publications